Prognostic value of a microRNA signature in nasopharyngeal carcinoma: A microRNA expression analysis

The Lancet Oncology

Volumn 13, Issue 6, 2012, Pages 633-641

  Liu, Na ^a   Chen, Nian Yong ^b   Cui, Rui Xue ^a   Li, Wen Fei ^a   Li, Yan ^b   Wei, Rong Rong ^a   Zhang, Mei Yin ^a   Sun, Ying ^a   Huang, Bi Jun ^a   Chen, Mo ^a   He, Qing Mei ^a   Jiang, Ning ^a   Chen, Lei ^a   Cho, William C S ^c   Yun, Jing Ping ^a   Zeng, Jing ^a   Liu, Li Zhi ^a   Li, Li ^a   Guo, Ying ^a   Wang, Hui Yun ^a   Ma, Jun ^a   more..

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SICHUAN UNIVERSITY   (China)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CHILD; CHINA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINOPHARYNGITIS; SCHOOL CHILD; SCORING SYSTEM;

ADULT; AGED; CHINA; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PARAFFIN EMBEDDING; PHARYNGECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861572492     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70102-X     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Cuardo MP, Edwards BK, Shin HR, et al. Cancer incidence in five continents 2007, Vol IX. International Agency for Research on Cancer, Lyon, France.
3. Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance image. Int J Radiat Oncol Biol Phys 2009, 73:1326-1334.
4. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006, 24:5414-5418.
5. Turen S, Ozyar E, Altundag K, Gullu I, Atahan IL Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Invest 2007, 25:315-321.
6. Lv X, Xiang YQ, Cao SM, et al. Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: more distant metastases and shorter overall survival after treatment. Head Neck 2011, 33:780-785.
7. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
8. Calin GA, Croce CM MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
9. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
10. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
11. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13:48-57.
12. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297:1901-1908.
13. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
14. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009, 361:1437-1447.
15. Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010, 11:136-146.
16. Cho WC MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010, 42:1273-1281.
17. Sengupta S, den Boon JA, Chen IH, et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 2008, 105:5874-5878.
18. Chen HC, Chen GH, Chen YH, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009, 100:1002-1011.
19. Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys 2008, 71:1356-1364.
20. Simon R, Radmacher MD, Dobbin K, McShane LM Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003, 95:14-18.
21. Korbler T, Grskovic M, Dominis M, Antica M A simple method for RNA isolation from formalin-fixed and paraffin-embedded lymphatic tissues. Exp Mol Pathol 2003, 74:336-340.
22. Wang HY, Luo M, Tereshchenko IV, et al. A genotyping system capable of simultaneously analyzing >1000 single nucleotide polymorphisms in a haploid genome. Genomen Res 2005, 15:276-283.
23. Wang H, Ach RA, Curry B Direct and sensitive miRNA profiling from low-input total RNA. RNA 2007, 13:151-159.
24. Biometric Research Branch-ArrayTools, (accessed Dec 1, 2009). http://linus.nci.nih.gov/BRB-ArrayTools.html.
25. MeV: MultiExperiment Viewer, (accessed Aug 1, 2008). http://www.tm4.org/mev.html.
26. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004, 350:1828-1837.
27. Chow SC, Shao J, Wang H Sample size calculations in clinical research 2003, Marcel Dekker, New York, USA.
28. Yang H-I, Yuen M-F, Chan HL-Y, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011, 12:568-574. for the REACH-B Working Group.
29. Marks JE, Philips JL, Menck HR, et al. The national cancer data base report on the relationship of race and national origin to the histology of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998, 83:582-588.
30. Hui EP, Leung SF, Au JS, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 2004, 101:300-306.
31. Leong SS, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinomas. Cancer 2005, 103:569-575.
32. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005, 3:3568-3576.
33. Cho WC MicroRNAs in cancer-from research to therapy. Biochim Biophys Acta 2010, 1805:209-217.